Proactive Investors - Run By Investors For Investors

Medlab CEO presents clinical NanaBis update to medical practitioners

The company is pleased with data it has collected to date for NanaBis.
Nanabis spray bottle
Medlab also sees a regulatory pathway for NanaBis to become an approved drug

Medlab Clinical Ltd’s (ASX:MDC) CEO Dr Sean Hall last night, presented a clinical NanaBis update to medical practitioners as part of on-going medical education.

He explained several key aspects of NanaBis, which is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).

A summary was provided of five case studies from five different doctors that were treated with NanaBis™ in Australia under the government-approved Special Access Scheme (SAS).

Notably, the data shows significant improvements in quality of life inclusive of sleep and movement with reduced pain/restriction, reduction/replacement of previously prescribed medication (in particular opioids, reduction in pain severity scores, and reduction of symptoms.

READ: Medlab Clinical does deal for global distribution of NanaBis

Medlab noted that it is extremely pleased with the pooled data collected to date as well as the ongoing regulatory pathway for an approved drug.

NanaBis wins head-to-head with approved cannabis drug

Further to previously announced Stage 1 results, NanaBis™ data from that component of the trial was directly compared to published data for an ARTG approved Cannabis Drug.

The head to head comparison demonstrates a similar plasma level of THC and CBD with NanaBis being half the dose.

Similarly, the rate of absorption for NanaBis was faster.

Actively pursuing drug approval

Based on trial activity, Medlab is actively pursuing regulatory pathways for  TGA in Australia, FDA in the US and Europe’s EMA.

Medlab has a planned framework that should take NanaBis to an approved drug.

Proactive caught up with Dr Hall earlier this week for an update

 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
data graphic
Fri
The Toronto company is busy meeting what it says is significant demand by building a data asset covering the medical cannabis sector
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use